Memantine Hydrochloride Tablet, Film Coated
Product Images NDC 71610-979

Product Visual Gallery

This gallery contains 12 technical images submitted to the FDA as part of the official labeling for Memantine Hydrochloride (NDC 71610-979). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aphena Pharma Solutions - Tennessee, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (16cd3370 8ddc 4dbb 82b3 98e128fb3482 01)

Chemical structure of memantine hydrochloride showing its adamantane backbone with amino and methyl substitutions, along with the hydrochloride moiety.*

FDA Label Image

Figure 1 (16cd3370 8ddc 4dbb 82b3 98e128fb3482 02)

Line graph showing mean (± SEM) change from baseline in ADCS-ADL score over 28 weeks of treatment for Memantine Hydrochloride and placebo groups. The graph depicts clinical improvement and decline with Memantine Hydrochloride showing less decline compared to placebo across the treatment period.*

FDA Label Image

Figure 2 (16cd3370 8ddc 4dbb 82b3 98e128fb3482 03)

A line graph comparing cumulative percentage of patients versus ADCS-ADL change from baseline for Memantine Hydrochloride and placebo groups. Data points for Memantine Hydrochloride are marked with circles, showing higher cumulative percentages at greater baseline changes, while placebo is marked with squares.*

FDA Label Image

Figure 3 (16cd3370 8ddc 4dbb 82b3 98e128fb3482 04)

A line graph compares the mean change from baseline in SIB scores over 28 weeks of treatment between placebo and memantine hydrochloride groups. The X-axis shows weeks of treatment (0 to 28), and the Y-axis shows mean change in SIB score from baseline with error bars. Data indicate clinical improvement for memantine hydrochloride and clinical decline for placebo over time.*

FDA Label Image

Figure 4 (16cd3370 8ddc 4dbb 82b3 98e128fb3482 05)

A cumulative percentage of patients graph showing SIB (Severe Impairment Battery) change from baseline for Memantine Hydrochloride versus placebo. The x-axis represents SIB change from baseline, and the y-axis represents the cumulative percentage of patients. Memantine Hydrochloride is indicated by open circles, and placebo by filled squares, demonstrating a greater patient improvement with Memantine Hydrochloride.*

FDA Label Image

Figure 5 (16cd3370 8ddc 4dbb 82b3 98e128fb3482 06)

A line graph comparing mean change from baseline in ADAS-cog scores over 24 weeks of treatment between two groups: Placebo/Donepezil and Memantine Hydrochloride/Donepezil. The x-axis shows weeks of treatment, and the y-axis shows mean change in score, with markers indicating clinical improvement and decline. Error bars represent standard error of the mean.*

FDA Label Image

Figure 6 (16cd3370 8ddc 4dbb 82b3 98e128fb3482 07)

A cumulative percentage of patients line graph comparing the effects of Placebo/Donepezil versus Memantine Hydrochloride/Donepezil on ADCS-ADL change from baseline. The x-axis represents change from baseline, and the y-axis represents the cumulative percentage of patients, showing treatment response distributions.*

FDA Label Image

Figure 7 (16cd3370 8ddc 4dbb 82b3 98e128fb3482 08)

A line graph comparing mean (±SEM) change from baseline in SIB score over 24 weeks of treatment for Placebo/Donepezil and Memantine Hydrochloride/Donepezil groups. The y-axis shows clinical improvement versus decline, while the x-axis shows weeks of treatment. Memantine Hydrochloride/Donepezil group demonstrates greater clinical improvement than Placebo/Donepezil.*

FDA Label Image

Figure 8 (16cd3370 8ddc 4dbb 82b3 98e128fb3482 09)

A line graph comparing the cumulative percentage of patients versus SIB (Severe Impairment Battery) change from baseline for two groups: Placebo/Donepezil and Memantine Hydrochloride/Donepezil. The x-axis displays SIB change from baseline, and the y-axis shows the cumulative percentage of patients.*

FDA Label Image

Company Logo (16cd3370 8ddc 4dbb 82b3 98e128fb3482 10)

FDA Label Image

Label (71610 0979 80)

Memantine Hydrochloride USP 5 mg film-coated tablets bottle label from Aphena Pharma Solutions - Tennessee, LLC. The label states a quantity of 180 tablets with storage instructions and handling warnings. The NDC is 71610-979-80, and the label includes manufacturing and packaging information, batch number, and barcodes.*

FDA Label Image

Aphena (Aphena)

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.